{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:10:13Z","timestamp":1787314213727,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11154-025-10002-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:08:01Z","timestamp":1761721681000},"page":"109-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pegvisomant in managing comorbidities of acromegaly: a review"],"prefix":"10.1007","volume":"27","author":[{"given":"Thierry","family":"Brue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Cristante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Espiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Peyrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassila","family":"A\u00efssani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"10","key":"10002_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"10002_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","volume":"97","author":"N Ershadinia","year":"2022","unstructured":"Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc. 2022;97(2):333\u201346.","journal-title":"Mayo Clin Proc"},{"key":"10002_CR3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","author":"A Giustina","year":"2020","unstructured":"Giustina A, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgz096.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10002_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268\u2013332.","journal-title":"Endocr Rev"},{"issue":"1","key":"10002_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EJE-08-0910","volume":"161","author":"M Buchfelder","year":"2009","unstructured":"Buchfelder M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol. 2009;161(1):27\u201335.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10002_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, et al. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10002_CR7","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00701-023-05772-7","volume":"165","author":"CM Falch","year":"2023","unstructured":"Falch CM, et al. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir (Wien). 2023;165(10):3003\u201310.","journal-title":"Acta Neurochir (Wien)"},{"key":"10002_CR8","doi-asserted-by":"crossref","unstructured":"Shin MS, et al. Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. Neurosurgery 2013; 73(3): 473\u20139 quiz 479.","DOI":"10.1227\/01.neu.0000431480.87160.84"},{"key":"10002_CR9","unstructured":"Zamanipoor Najafabadi AH, et al. Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. Endocr Connect, 2023. 12(1)."},{"issue":"6","key":"10002_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s12325-009-0035-4","volume":"26","author":"F Castinetti","year":"2009","unstructured":"Castinetti F, et al. Lanreotide for the treatment of acromegaly. Adv Ther. 2009;26(6):600\u201312.","journal-title":"Adv Ther"},{"key":"10002_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","volume":"12","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, et al. Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). 2021;12:648411.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"13","key":"10002_CR12","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.2165\/11204510-000000000-00000","volume":"70","author":"LP Yang","year":"2010","unstructured":"Yang LP, Keating GM. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2010;70(13):1745\u201369.","journal-title":"Drugs"},{"issue":"5","key":"10002_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1530\/EJE-15-0500","volume":"173","author":"E Kuhn","year":"2015","unstructured":"Kuhn E, et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur J Endocrinol. 2015;173(5):693\u2013702.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10002_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/neuonc\/noz225","volume":"22","author":"R Kotecha","year":"2020","unstructured":"Kotecha R, et al. Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion. Neuro Oncol. 2020;22(3):318\u201332.","journal-title":"Neuro Oncol"},{"issue":"4","key":"10002_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.rpor.2014.09.004","volume":"21","author":"G Minniti","year":"2016","unstructured":"Minniti G, et al. Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother. 2016;21(4):370\u20138.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"10002_CR16","doi-asserted-by":"publisher","first-page":"e1323","DOI":"10.1210\/clinem\/dgad568","volume":"109","author":"MR Gadelha","year":"2024","unstructured":"Gadelha MR, Gadelha AC, Kasuki L. New treatments for acromegaly in development. J Clin Endocrinol Metab. 2024;109(4):e1323-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10002_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ando.2023.08.003","volume":"84","author":"T Brue","year":"2023","unstructured":"Brue T, et al. Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP). Ann Endocrinol (Paris). 2023;84(6):697\u2013710.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"10002_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ando.2015.10.003","volume":"76","author":"P Chanson","year":"2015","unstructured":"Chanson P, et al. Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY. Ann Endocrinol (Paris). 2015;76(6):664\u201370.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"10002_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525\u201338.","journal-title":"Eur J Endocrinol"},{"issue":"13","key":"10002_CR20","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1073\/pnas.87.13.5061","volume":"87","author":"WY Chen","year":"1990","unstructured":"Chen WY, et al. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci U S A. 1990;87(13):5061\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10002_CR21","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1073\/pnas.88.8.3407","volume":"88","author":"BC Cunningham","year":"1991","unstructured":"Cunningham BC, Wells JA. Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci U S A. 1991;88(8):3407\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10002_CR22","first-page":"1716","volume":"86","author":"RJ Ross","year":"2001","unstructured":"Ross RJ, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab. 2001;86(4):1716\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10002_CR23","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1530\/EC-18-0047","volume":"7","author":"G Johannsson","year":"2018","unstructured":"Johannsson G, et al. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Connect. 2018;7(3):R126\u201334.","journal-title":"Endocr Connect"},{"issue":"1","key":"10002_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, et al. A pituitary society update to acromegaly management guidelines. Pituitary. 2021;24(1):1\u201313.","journal-title":"Pituitary"},{"issue":"6","key":"10002_CR25","first-page":"2098","volume":"84","author":"MO Thorner","year":"1999","unstructured":"Thorner MO. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab. 1999;84(6):2098\u2013103.","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10002_CR26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171\u20137.","journal-title":"N Engl J Med"},{"issue":"9295","key":"10002_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ van der Lely","year":"2001","unstructured":"van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754\u20139.","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10002_CR28","first-page":"70","volume":"68","author":"CJ Strasburger","year":"2007","unstructured":"Strasburger CJ, et al. Experience from the German pegvisomant observational study. Horm Res. 2007;68(Suppl 5):70\u20133.","journal-title":"Horm Res"},{"issue":"4","key":"10002_CR29","first-page":"328","volume":"63","author":"CL Boguszewski","year":"2019","unstructured":"Boguszewski CL, et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch Endocrinol Metab. 2019;63(4):328\u201336.","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"10002_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.20945\/2359-3997000000160","volume":"63","author":"NXG Basavilbaso","year":"2019","unstructured":"Basavilbaso NXG, et al. Pegvisomant in acromegaly: a multicenter real-life study in Argentina. Arch Endocrinol Metab. 2019;63(4):320\u20137.","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"10002_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1507\/endocrj.EJ19-0266","volume":"67","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, et al. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocr J. 2020;67(2):201\u201310.","journal-title":"Endocr J"},{"issue":"1","key":"10002_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","volume":"63","author":"LP Leonart","year":"2019","unstructured":"Leonart LP, et al. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine. 2019;63(1):18\u201326.","journal-title":"Endocrine"},{"issue":"8","key":"10002_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102921","volume":"54","author":"P Wolf","year":"2023","unstructured":"Wolf P, et al. Acromegalic cardiomyopathy: an entity on its own? The effects of GH and IGF-I excess and treatment on cardiovascular risk factors. Arch Med Res. 2023;54(8):102921.","journal-title":"Arch Med Res"},{"issue":"9","key":"10002_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/BF03346667","volume":"33","author":"MC De Martino","year":"2010","unstructured":"De Martino MC, et al. The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest. 2010;33(9):663\u201370.","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"10002_CR35","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1210\/jc.2009-2570","volume":"95","author":"C Berg","year":"2010","unstructured":"Berg C, et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95(8):3648\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10002_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-0029-1214386","volume":"117","author":"BL Herrmann","year":"2009","unstructured":"Herrmann BL, et al. Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin Endocrinol Diabetes. 2009;117(8):417\u201322.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10002_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1210\/jc.2006-1587","volume":"92","author":"R Pivonello","year":"2007","unstructured":"Pivonello R, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007;92(2):476\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10002_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/EJE-12-0596","volume":"168","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol. 2013;168(1):15\u201322.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10002_CR39","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","volume":"87","author":"G Sesmilo","year":"2002","unstructured":"Sesmilo G, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab. 2002;87(4):1692\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10002_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-13-0438","volume":"171","author":"M Droste","year":"2014","unstructured":"Droste M, et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014;171(1):59\u201368.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10002_CR41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1210\/jc.2013-3264","volume":"99","author":"A Thankamony","year":"2014","unstructured":"Thankamony A, et al. Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes. J Clin Endocrinol Metab. 2014;99(2):639\u201347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10002_CR42","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"Higham CE, et al. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab. 2009;94(7):2459\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"10002_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferrau","year":"2018","unstructured":"Ferrau F, et al. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (Lausanne). 2018;9:358.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10002_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"Brue T, et al. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine. 2019;63(3):563\u201372.","journal-title":"Endocrine"},{"issue":"3","key":"10002_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","volume":"56","author":"C Parkinson","year":"2002","unstructured":"Parkinson C, et al. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf). 2002;56(3):303\u201311.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10002_CR46","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","volume":"21","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, et al. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary. 2018;21(3):302\u20138.","journal-title":"Pituitary"},{"issue":"2","key":"10002_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12020-017-1391-5","volume":"59","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, et al. Prevalence of morphometric vertebral fractures in \u201cdifficult\u201d patients with acromegaly with different biochemical outcomes after multimodal treatment. Endocrine. 2018;59(2):449\u201353.","journal-title":"Endocrine"},{"issue":"6","key":"10002_CR48","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40618-023-02281-3","volume":"47","author":"E Vitali","year":"2024","unstructured":"Vitali E, et al. The direct impact of pegvisomant on osteoblast functions and bone development. J Endocrinol Invest. 2024;47(6):1385\u201394.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"10002_CR49","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae079","volume":"8","author":"AP Kuker","year":"2024","unstructured":"Kuker AP, et al. Long-term Pegvisomant therapy of acromegaly: effects on bone density, turnover and microstructure using HRpQCT. J Endocr Soc. 2024;8(6):bvae079.","journal-title":"J Endocr Soc"},{"issue":"6","key":"10002_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1530\/EJE-09-0694","volume":"161","author":"C Berg","year":"2009","unstructured":"Berg C, et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur J Endocrinol. 2009;161(6):829\u201335.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10002_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2265.2009.03773.x","volume":"73","author":"C Sievers","year":"2010","unstructured":"Sievers C, et al. Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol (Oxf). 2010;73(1):89\u201394.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10002_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12020-023-03462-z","volume":"82","author":"C Fajardo","year":"2023","unstructured":"Fajardo C, et al. Preference of acromegaly patients for treatment attributes in Spain. Endocrine. 2023;82(2):379\u201389.","journal-title":"Endocrine"},{"issue":"Suppl 1","key":"10002_CR53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000329189","volume":"76","author":"SJ Neggers","year":"2011","unstructured":"Neggers SJ, van der Lely AJ. Pegvisomant and improvement of quality of life in acromegalic patients. Horm Res Paediatr. 2011;76(Suppl 1):102\u20135.","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"10002_CR54","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJ Neggers","year":"2008","unstructured":"Neggers SJ, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10002_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11102-013-0544-7","volume":"17","author":"H Kepicoglu","year":"2014","unstructured":"Kepicoglu H, et al. Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary. 2014;17(6):557\u201363.","journal-title":"Pituitary"},{"issue":"3","key":"10002_CR56","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","volume":"25","author":"R Salvatori","year":"2022","unstructured":"Salvatori R, et al. Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience. Pituitary. 2022;25(3):420\u201332.","journal-title":"Pituitary"},{"issue":"1","key":"10002_CR57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cen.14309","volume":"94","author":"LE Dichtel","year":"2021","unstructured":"Dichtel LE, et al. Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clin Endocrinol (Oxf). 2021;94(1):58\u201365.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10002_CR58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-07-0697","volume":"158","author":"MP Matta","year":"2008","unstructured":"Matta MP, et al. Impaired quality of life of patients with acromegaly: control of GH\/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol. 2008;158(3):305\u201310.","journal-title":"Eur J Endocrinol"},{"key":"10002_CR59","unstructured":"Badireddy M, and Baradhi KM Chronic Anemia, in StatPearls. 2023: Treasure Island (FL) ineligible companies. Disclosure: Krishna Baradhi declares no relevant financial relationships with ineligible companies."},{"key":"10002_CR60","unstructured":"Pegvisomant SOPC-. EMA"},{"issue":"1","key":"10002_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-08-0990","volume":"161","author":"CE Higham","year":"2009","unstructured":"Higham CE, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009;161(1):21\u20135.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10002_CR62","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-10-0867","volume":"164","author":"AJ van der Lely","year":"2011","unstructured":"van der Lely AJ, et al. Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164(3):325\u201333.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10002_CR63","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1210\/jc.2014-2032","volume":"99","author":"SJ Neggers","year":"2014","unstructured":"Neggers SJ, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014;99(10):3644\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"10002_CR64","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa444","author":"V Bonert","year":"2020","unstructured":"Bonert V, et al. Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa444.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10002_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2025.101811","volume":"86","author":"G Raverot","year":"2025","unstructured":"Raverot G, et al. Cost-utility analysis of second line acromegaly treatment in France. Ann Endocrinol (Paris). 2025;86(5):101811.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"10","key":"10002_CR66","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/0003-4819-147-10-200711200-00019","volume":"147","author":"M Marazuela","year":"2007","unstructured":"Marazuela M, et al. Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med. 2007;147(10):741\u20133.","journal-title":"Ann Intern Med"},{"issue":"4","key":"10002_CR67","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2265.2008.03400.x","volume":"70","author":"C Salvatore","year":"2009","unstructured":"Salvatore C, et al. Subcutaneous lipoatrophy induced by long-term pegvisomant administration. Clin Endocrinol (Oxf). 2009;70(4):655\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10002_CR68","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/cen.12440","volume":"81","author":"G Sesmilo","year":"2014","unstructured":"Sesmilo G, et al. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin Endocrinol (Oxf). 2014;81(6):883\u201390.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10002_CR69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","volume":"22","author":"R Camara","year":"2019","unstructured":"Camara R, et al. Treatment adherence to pegvisomant in patients with acromegaly in Spain: pegaso study. Pituitary. 2019;22(2):137\u201345.","journal-title":"Pituitary"},{"issue":"1","key":"10002_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-0545-2","volume":"20","author":"L Ma","year":"2020","unstructured":"Ma L, et al. Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies. BMC Endocr Disord. 2020;20(1):126.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10002_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1210\/clinem\/dgae444","volume":"110","author":"M Marques-Pamies","year":"2024","unstructured":"Marques-Pamies M, et al. Personalized medicine in Acromegaly: the ACROFAST study. J Clin Endocrinol Metab. 2024;110(1):30\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10002_CR72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1210\/jc.2009-1912","volume":"95","author":"P Attal","year":"2010","unstructured":"Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010;95(2):483\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"10002_CR73","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz116","author":"M Parolin","year":"2020","unstructured":"Parolin M, et al. Obstructive sleep apnea in acromegaly and the effect of treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgz116.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10002_CR74","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s11102-024-01465-1","volume":"27","author":"ICM Pelsma","year":"2024","unstructured":"Pelsma ICM, et al. Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management. Pituitary. 2024;27(6):824\u201336.","journal-title":"Pituitary"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-10002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-025-10002-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-10002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:07:40Z","timestamp":1775034460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-025-10002-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10002"],"URL":"https:\/\/doi.org\/10.1007\/s11154-025-10002-9","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"29 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.R. reports receiving research contracts from Amolyt, Pfizer, Recordati, and Novo Nordisk, all of which were paid to his institution (Hospices Civils de Lyon), with no personal remuneration. G.R. is also a principal investigator in clinical trials sponsored by Ascendis, Recordati, and Pfizer. T.B. has received research contracts from Pfizer and Novo Nordisk. T.B. has served as a consultant for Pfizer, Recordati, and Novo Nordisk, and has acted as a clinical trial investigator for Crinetics, Debiopharm, and Recordati. S.E. has received congress support and hospitality from Pfizer SAS and has participated in non-remunerated scientific collaborations. P.C. has received unrestricted research and educational grants from Ipsen, Recordati, Advanz, and Pfizer in his capacity as Head of the Department of Endocrinology and Reproductive Diseases, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay. P.C. has served as principal or coordinating investigator in clinical trials sponsored by Chiasma, Recordati, Pfizer, Crinetics, and Debiopharm. P.C. is a member of advisory boards for Pfizer, Recordati, and Amolyt\/Alexion, and has given lectures for Ipsen, Recordati, and Pfizer. All fees and honoraria were paid to his institution or affiliated research association. D.D. has received congress invitations and speaker fees from Pfizer related to the topic of the current work. J.C. has received congress support and other benefits from HRA, Parexel, Recordati, Pfizer, and Sanofi. W.A. and L.P. are employees of Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}